Dr Horwitz speaks with ecancer at the 2017 ASH annual meeting about results from the phase III MAVORIC study, looking at mogamulizumab versus vorinostat in patients with previously treated cutaneous T-cell lymphoma.
He highlighted that in the first report evaluating progression free survival as a primary endpoint in cutaneous T-cell lymphoma, mogamulizumab demonstrated significantly superior progression free survival, overall response rate, and quality of life compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma.
Read the news story for more.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.